Aminopeptidase N(APN/CD13), a Zn<sup>2+</sup>-dependent ectopeptidase localized on the cell surface, is widely considered to influence the invasion of tumor cells. We found that boroleucine and dino-leucin...Aminopeptidase N(APN/CD13), a Zn<sup>2+</sup>-dependent ectopeptidase localized on the cell surface, is widely considered to influence the invasion of tumor cells. We found that boroleucine and dino-leucine borate exhibited a strong inhibitory effect on the enzyme activity of aminopeptidase N. The tested assay indicated that both compounds had an anti-proliferative effect on triple-negative breast cancer cells. Wound healing assay, migration test and matrigel-coated transwell assay showed that both boroleucine and dino-leucine borate inhibited the migration and invasion of breast cancer cells. Immunoblot analysis showed that both compounds down-regulated the expression of matrix metalloproteinase-2/9. In the capillary tube formation assay of human umbilical vein endothelial cells (HUVECs), dino-leucine borate showed better antiangiogenic activity than ubenimex even at a low concentration (10 μM). Moreover, compared with ubenimex, the anti-metastatic activity of dino-leucine borate in vivo was similar to or even better than that of ubenimex in the H22 pulmonary metastasis mouse model. In this paper, we found the novel APN inhibitors to markedly suppress the enzyme activity of APN and inhibit the migration and invasion of tumor cells in vitro and in vivo.展开更多
Pancreatic cancer is a malignant disease characterized by low survival and high recurrence rate,whose patients are mostly at the stage of locally advanced or metastatic disease when first diagnosed.Early diagnosis is ...Pancreatic cancer is a malignant disease characterized by low survival and high recurrence rate,whose patients are mostly at the stage of locally advanced or metastatic disease when first diagnosed.Early diagnosis is particularly important because prognostic/predictive markers help guide optimal individualized treatment regimens.So far,CA19-9 is the only biomarker for pancreatic cancer approved by the FDA,but its effectiveness is limited by low sensitivity and specificity.With recent advances in genomics,proteomics,metabolomics,and other analytical and sequencing technologies,the rapid acquisition and screening of biomarkers is now possible.Liquid biopsy also occupies a significant place due to its unique advantages.In this review,we systematically describe and evaluate the available biomarkers that have the greatest potential as vital tools in diagnosing and treating pancreatic cancer.展开更多
文摘Aminopeptidase N(APN/CD13), a Zn<sup>2+</sup>-dependent ectopeptidase localized on the cell surface, is widely considered to influence the invasion of tumor cells. We found that boroleucine and dino-leucine borate exhibited a strong inhibitory effect on the enzyme activity of aminopeptidase N. The tested assay indicated that both compounds had an anti-proliferative effect on triple-negative breast cancer cells. Wound healing assay, migration test and matrigel-coated transwell assay showed that both boroleucine and dino-leucine borate inhibited the migration and invasion of breast cancer cells. Immunoblot analysis showed that both compounds down-regulated the expression of matrix metalloproteinase-2/9. In the capillary tube formation assay of human umbilical vein endothelial cells (HUVECs), dino-leucine borate showed better antiangiogenic activity than ubenimex even at a low concentration (10 μM). Moreover, compared with ubenimex, the anti-metastatic activity of dino-leucine borate in vivo was similar to or even better than that of ubenimex in the H22 pulmonary metastasis mouse model. In this paper, we found the novel APN inhibitors to markedly suppress the enzyme activity of APN and inhibit the migration and invasion of tumor cells in vitro and in vivo.
基金This work was supported by Beijing Natural Science Foundation(7212157,China)CAMS Innovation Fund for Medical Sciences(2021-I2M-1-029 and 2022-12M-JB-011,China)National Natural Science Foundation of China(81703536,China).
文摘Pancreatic cancer is a malignant disease characterized by low survival and high recurrence rate,whose patients are mostly at the stage of locally advanced or metastatic disease when first diagnosed.Early diagnosis is particularly important because prognostic/predictive markers help guide optimal individualized treatment regimens.So far,CA19-9 is the only biomarker for pancreatic cancer approved by the FDA,but its effectiveness is limited by low sensitivity and specificity.With recent advances in genomics,proteomics,metabolomics,and other analytical and sequencing technologies,the rapid acquisition and screening of biomarkers is now possible.Liquid biopsy also occupies a significant place due to its unique advantages.In this review,we systematically describe and evaluate the available biomarkers that have the greatest potential as vital tools in diagnosing and treating pancreatic cancer.
